<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452163</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-16-03</org_study_id>
    <nct_id>NCT03452163</nct_id>
  </id_info>
  <brief_title>Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit</brief_title>
  <official_title>Performance Assessment of the Physiological Monitor Device (PMD-200), a Novel Pain Monitor, in Subjects at Neurointensive Care Unit (NICU).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medasense Biometrics Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medasense Biometrics Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Performance Assessment of the PMD-200, a Novel Pain Monitor, in Subjects at Neurointensive&#xD;
      Care Unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is design to further demonstrates the performance of the Nociception Level&#xD;
      (NoL) Index in neurological impaired anesthetized patients under general anesthesia, by&#xD;
      evaluating its response to controlled changes in the levels of noxious stimuli/analgesia, and&#xD;
      to correlate the NoL response to the EEG derived pain score. Validating the performance of&#xD;
      the NoL Index may provide a tool to monitor the pain/nociception in this population.&#xD;
&#xD;
      In this study, the PI plan to demonstrate that the NoL Index is a continuous index. It is&#xD;
      anticipated that a higher level of nociception will correspond to a higher NoL index. On the&#xD;
      other hand, it is anticipated that higher levels of analgesic agent for the same noxious&#xD;
      stimulus will lead to a lower NoL index.&#xD;
&#xD;
      The participants will be monitored as in a typical ICU and according to the local guidelines&#xD;
      by various types of monitoring devices, such as: vital signs, pulse oximeter, Bispectral&#xD;
      Index (BIS), Electroencephalography (EEG) etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to support study performance&#xD;
  </why_stopped>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between changes in the nociception levels of the subject (NoL Index value) prior and following a noxious stimuli</measure>
    <time_frame>Through study completion, about one year</time_frame>
    <description>To demonstrate that the NoL Index is correlates with changes in the nociception levels of the subject prior and following a noxious stimuli.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between changes in the nociception levels of the subject (NoL Index value) to other nociception predictors (HR, NIBP)</measure>
    <time_frame>Through study completion, about one year</time_frame>
    <description>The NoL values can be correlate to other nociception predictors (e.g heart rate, blood pressure) following a noxious stimuli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the NoL index and the EEG derived pain score</measure>
    <time_frame>Through study completion, about one year</time_frame>
    <description>To assess the correlation between the NoL index and the EEG derived pain score during arousal response caused by noxious stimuli</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>Anesthesia, General</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PMD-200</intervention_name>
    <description>the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoLâ„¢ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is &quot;no pain/nociception&quot; and 100 is &quot;extreme pain/nociception&quot;.</description>
    <arm_group_label>Anesthesia, General</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EEG monitor</intervention_name>
    <description>An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.</description>
    <arm_group_label>Anesthesia, General</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old.&#xD;
&#xD;
          -  The subject is under general anesthesia&#xD;
&#xD;
          -  The subject have a blood pressure measurement (either arterial or cuff) during the&#xD;
             study&#xD;
&#xD;
          -  A signed Informed Consent Form (ICF) has been obtain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - The subject is constantly agitate or moving a lot&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Soustiel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurosurgery Galilee Medical Center, Nahariya, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galil Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>May 2, 2021</last_update_submitted>
  <last_update_submitted_qc>May 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

